Study team will plan a prospective, randomized control trial using our institution's spine clinical outcomes registry. Eligible patients undergoing ACDF (see inclusion criteria listed below) will be randomized to an Intervention or Control Group, which will differ according to the interbody cage used during the procedure. In the Intervention Group (100 patients), Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology will be implanted at each treated level. In the Control Group (100 patients), patients will receive an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology. Interbody cages used in the Control Group (along with the decision to apply anterior plate fixation) will be determined according to surgeon preference. There will be no blinding to the type of implant used. Standard demographic and procedural variables will be collected for all patients (including history of diabetes, tobacco, use, prior use of oral corticosteroids, number of levels fused, and presence of bicortical screw placement). Clinical and radiographic outcomes in the Intervention and Control Groups will be directly compared.
Age range
18 Years – 99 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of patient reported dysphagia events measured by Eat-10 assessment tool
Timeframe: Postoperative at Day 1
Number of patient reported dysphagia events measured by Eat-10 assessment tool
Timeframe: 2 weeks following surgery
Number of patient reported dysphagia events measured by Eat-10 assessment tool
Timeframe: 3 months following surgery
Number of patient reported dysphagia events measured by Eat-10 assessment tool
Timeframe: 6 months following surgery
Number of patient reported dysphagia events measured by Eat-10 assessment tool
Timeframe: 12 months following surgery
Dysphagia as measured by SWAL-QOL assessment tool
Timeframe: Postoperative at day 1
Dysphagia as measured by SWAL-QOL assessment tool
Timeframe: 2 weeks following surgery
Dysphagia as measured by SWAL-QOL assessment tool
Timeframe: 3 months following surgery
Dysphagia as measured by SWAL-QOL assessment tool
Timeframe: 6 months following surgery
Dysphagia as measured by SWAL-QOL assessment tool
Timeframe: 12 months following surgery
Degree of radiographic fusion
Timeframe: 6 weeks following surgery
Degree of radiographic fusion
Timeframe: 3 months following surgery
Degree of radiographic fusion
Timeframe: 6 months following surgery
Degree of radiographic fusion
Timeframe: 12 months following surgery
Incidence of radiographic adjacent segment disease
Timeframe: 6 months following surgery
Incidence of radiographic adjacent segment disease
Timeframe: 12 months following surgery